At a Glance

We are eFFECTOR Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). We believe that our therapeutic approach can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit, all while preserving normal cell function. We are currently evaluating our lead product candidate, zotatifin, an inhibitor of eIF4A, in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. Tomivosertib, an oral small molecule inhibitor of MNK, is currently being studied in an investigator led trial by Northwestern University in patients with AML. Additionally, we have a global collaboration with Pfizer to develop eIF4E inhibitors.

We are headquartered in Solana Beach, California.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


06.18.2024 2:23 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.